The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.
Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.
Using a combination of micro-needling and exosome injections as a potential treatment for male pattern baldness, which could result in 50% or more regrowth.
Exosomes from Musely are being discussed as a topical hair loss treatment containing ingredients like latanoprost, caffeine, cetirizine, melatonin, vitamin D3, vitamin E, and biotin. Users are curious about its effectiveness and potential side effects, noting it may take 4-6 months to see results.
The conversation discusses new hair loss treatments like stem cell therapy, exosome treatments, and DHI, with mentions of GT20029, Amp303, and Plated PRP Serum as promising options. It also notes the use of dutasteride, topical finasteride, and minoxidil, but the focus is on non-hormonal innovations.
A 28-year-old experiencing worsening hair loss despite using Dutasteride and oral Minoxidil is considering exosometherapy and possibly switching treatments due to side effects. They seek advice on whether to continue with Dutasteride or try alternatives like Pyrilutamide or topical supplements.
A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.
A user inquired about Hair XL offered by a clinic in the Netherlands, questioning if it is a form of Exosome treatment. The conversation seeks experiences and clarity on the treatment.
The user is one month into their FUE treatment and has just undergone PRP treatment at American Mane in Miami. They plan to start using minoxidil and LLT, take xpecia with saw palmetto, and try Exosome from ExoScrt and PRP for better hair growth results.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
The conversation is about a new acne treatment cream called Clascoterone Cream 1%, which is the first new mechanism of action for acne in nearly 40 years. One person joked about hoping their face will be as clean as their bald head after using the cream.
A new hair loss treatment using dermal exosomes can restore up to 90% of lost hair in mice. Users discuss potential human trials and compare it to Minoxidil and Finasteride.
A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.
The conversation discusses the potential of developing a selective oral SARM to target androgen activity in the scalp and skin, as an alternative to oral Dutasteride and Finasteride, which have systemic side effects. It also mentions Clascoterone and RU58841 as topical treatments for hair loss.
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.
The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.
Clascoterone, an acne treatment that blocks DHT, is being developed for scalp use against hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.
The conversation is about a 21-year-old male inquiring about the effectiveness of exosometherapy for hair thinning on the crown and considering whether to start Minoxidil while already on Finasteride and having had exosome injections 15 days ago.
Topical dutasteride with microneedling and mesotherapy dutasteride injections are effective treatments for androgenetic alopecia in both men and women. These methods offer promising alternatives to oral therapies with potentially fewer systemic side effects.
The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.
User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.
A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.
A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.
The user is disappointed with their hair loss progress after six months of using oral medications, laser therapy, microneedling, and vitamin D supplements. They are considering exosometherapy but are unsure of its effectiveness and are seeking advice on whether to continue or try other treatments.
The conversation discusses the use of Dutasteride scalp injections (mesotherapy) for hair loss. Users are sharing their experiences and seeking information on its effectiveness.